SciClone Reaches Agreement to Settle FCPA Derivative Suit

The suit — a consolidation of four similar plaintiff’s actions — alleged the Foster City, Calif.-based drugmaker made material misstatements about its financial results based on allegedly illegal and improper sales and marketing activities of hepatitis drug Zadaxin in China.

This story is exclusively for members of the
E-mail Address or UserName: *
Password: *
Click here to subscribe to
Just Anti-Corruption

For information about pricing, click here.
Barnes & Thornburg LLP
ANALYSIS: “Hide No Harm Act Of 2015” Targets Employers, Directors and Officers more
Sheppard, Mullin, Richter & Hampton LLP
ANALYSIS: The Schrems Decision: How the End of Safe Harbor Affects Your FCPA Compliance Plan more
Paul Hastings LLP
ANALYSIS: The Yates Memorandum: Increasing the Perils of Parallel Proceedings more
Arnold & Porter LLP
ANALYSIS: Global Reach? Extraterritorial Application of US Criminal Law  more
Dechert LLP
ANALYSIS: U.S. Chamber of Commerce Joins Chorus Pushing For Overhaul in SEC Enforcement Practices more
Orrick, Herrington & Sutcliffe LLP
ANALYSIS: There’s a New Sheriff In Town: Coverage for World Bank Investigations and Sanctions more
An error has occurred, which probably means the feed is down. Try again later.